| P2093 | author name string | Kenneth Hoyt | |
| | Reshu Saini | |
| P2860 | cites work | Assessment of a new mathematical model for the computation of numerical parameters related to renal cortical blood flow and fractional blood volume by contrast-enhanced ultrasound. | Q51618026 |
| | Quantification of flow using ultrasound and microbubbles: a disruption replenishment model based on physical principles. | Q51785680 |
| | A method for differentiating targeted microbubbles in real time using subharmonic micro-ultrasound and interframe filtering. | Q52594810 |
| | Contrast-enhanced ultrasound is helpful in the differentiation of malignant and benign breast lesions. | Q53346681 |
| | [Evaluation of early response to antiangiogenic treatment with dynamic contrast enhanced ultrasound] | Q53411921 |
| | Contrast-enhanced ultrasonography better identifies pancreatic tumor vascularization than helical CT. | Q53579816 |
| | Breast tumor vascularity identified by contrast enhanced ultrasound and pathology: initial results | Q73830602 |
| | Oncotic pressure in solid tumors is elevated | Q74181161 |
| | [Treatment of local recurrent melanomas by isolated limb perfusion: value of Doppler ultrasonography] | Q78753825 |
| | Quantitative contrast-enhanced ultrasound for imaging antiangiogenic treatment response in experimental osteolytic breast cancer bone metastases | Q84280240 |
| | Contrast-ultrasound dispersion imaging for prostate cancer localization by improved spatiotemporal similarity analysis | Q86989561 |
| | Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantification—Preliminary Results 1 | Q22255600 |
| | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| | A new formalism for the quantification of tissue perfusion by the destruction-replenishment method in contrast ultrasound imaging | Q28252532 |
| | Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion | Q28263850 |
| | Effects of acoustic radiation force on the binding efficiency of BR55, a VEGFR2-specific ultrasound contrast agent | Q28266482 |
| | Angiogenesis in cancer, vascular, rheumatoid and other disease | Q29547165 |
| | Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy | Q29547379 |
| | The biology of vascular endothelial growth factor | Q29615946 |
| | Tumorigenesis and the angiogenic switch | Q29619849 |
| | What Is the Evidence That Tumors Are Angiogenesis Dependent? | Q29620029 |
| | Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins | Q30310466 |
| | Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. | Q30310994 |
| | scVEGF microbubble ultrasound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis | Q30425448 |
| | Real-time technique for improving molecular imaging and guiding drug delivery in large blood vessels: in vitro and ex vivo results | Q30430526 |
| | US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice | Q30431243 |
| | Perfusion estimation using contrast-enhanced 3-dimensional subharmonic ultrasound imaging: an in vivo study | Q30431873 |
| | Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent. | Q30432690 |
| | Dual frequency method for simultaneous translation and real-time imaging of ultrasound contrast agents within large blood vessels | Q30434058 |
| | Influence of lipid shell physicochemical properties on ultrasound-induced microbubble destruction | Q30446982 |
| | Preparation of targeted microbubbles: ultrasound contrast agents for molecular imaging | Q30448551 |
| | Mapping microvasculature with acoustic angiography yields quantifiable differences between healthy and tumor-bearing tissue volumes in a rodent model | Q30450073 |
| | Three-dimensional subharmonic ultrasound imaging in vitro and in vivo | Q30453926 |
| | Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy | Q30454165 |
| | Assessment of molecular imaging of angiogenesis with three-dimensional ultrasonography | Q30454657 |
| | Microbubbles as ultrasound contrast agents for molecular imaging: preparation and application | Q30455865 |
| | An animal model allowing controlled receptor expression for molecular ultrasound imaging. | Q30458500 |
| | Contrast-enhanced ultrasonography of the rabbit VX2 tumor model: Analysis of vascular pathology | Q30460419 |
| | Microbubble therapy enhances anti-tumor properties of cisplatin and cetuximab in vitro and in vivo | Q30464657 |
| | Microbubble-mediated ultrasonic techniques for improved chemotherapeutic delivery in cancer | Q30464745 |
| | Model system using controlled receptor expression for evaluating targeted ultrasound contrast agents | Q30465343 |
| | Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). | Q30474689 |
| | Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks | Q30475052 |
| | Application of molecular ultrasound for imaging integrin expression | Q30475572 |
| | Multimodality molecular imaging of CD105 (Endoglin) expression | Q30476445 |
| | A sensitive TLRH targeted imaging technique for ultrasonic molecular imaging. | Q30477810 |
| | Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo | Q30484195 |
| | Molecular ultrasound imaging of early vascular response in prostate tumors irradiated with carbon ions. | Q30487248 |
| | Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography | Q30491474 |
| | Selective imaging of adherent targeted ultrasound contrast agents | Q30500211 |
| | Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers | Q30542073 |
| | Comparing contrast-enhanced color flow imaging and pathological measures of breast lesion vascularity | Q33330783 |
| | Sonographic depiction of tumor vascularity and flow: from in vivo models to clinical applications | Q33810950 |
| | Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents | Q34069068 |
| | BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis | Q34089383 |
| | VEGF-VEGF receptor complexes as markers of tumor vascular endothelium | Q34328588 |
| | Ultrasound contrast agents: properties, principles of action, tolerance, and artifacts | Q34344498 |
| | Contrast enhanced maximum intensity projection ultrasound imaging for assessing angiogenesis in murine glioma and breast tumor models: A comparative study | Q34536116 |
| | Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma | Q34570747 |
| | Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging | Q34591102 |
| | Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment | Q34765898 |
| | Contrast-enhanced computed tomography and ultrasound for the evaluation of tumor blood flow. | Q34803545 |
| | A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature | Q35118263 |
| | Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound | Q35759617 |
| | Quantitative mapping of tumor vascularity using volumetric contrast-enhanced ultrasound | Q35783072 |
| | P-selectin cell adhesion molecule in inflammation, thrombosis, cancer growth and metastasis | Q35848065 |
| | Cellular abnormalities of blood vessels as targets in cancer | Q36015542 |
| | Molecular targeting of ultrasonographic contrast agent for detection of head and neck squamous cell carcinoma | Q36158757 |
| | Molecular ultrasound imaging using a targeted contrast agent for assessing early tumor response to antiangiogenic therapy | Q36297117 |
| | Volumetric contrast-enhanced ultrasound imaging to assess early response to apoptosis-inducing anti-death receptor 5 antibody therapy in a breast cancer animal model | Q36576268 |
| | Optical fluorescent imaging to monitor temporal effects of microbubble-mediated ultrasound therapy. | Q36772860 |
| | Focused abdominal ultrasound in preoperative liver surgery staging: a prospective study | Q36952360 |
| | Delta-projection imaging on contrast-enhanced ultrasound to quantify tumor microvasculature and perfusion | Q37101638 |
| | Bioeffects considerations for diagnostic ultrasound contrast agents | Q37116582 |
| | Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. | Q37133833 |
| | Quantitative Volumetric Perfusion Mapping of the Microvasculature Using Contrast Ultrasound | Q37294756 |
| | Function and antagonism of beta3 integrins in the development of cancer therapy. | Q37515522 |
| | Contrast-enhanced ultrasound for molecular imaging of angiogenesis | Q37749577 |
| | Indicator dilution models for the quantification of microvascular blood flow with bolus administration of ultrasound contrast agents. | Q37763344 |
| | Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. | Q37898911 |
| | An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion | Q38030471 |
| | Liver dysplasia: US molecular imaging with targeted contrast agent enables early assessment | Q38077605 |
| | Ultrasound molecular imaging of E-selectin in tumor vessels using poly n-butyl cyanoacrylate microbubbles covalently coupled to a short targeting peptide | Q39125510 |
| | Regions of interest and parameters for the quantitative analysis of contrast-enhanced ultrasound to evaluate the anti-angiogenic effects of bevacizumab | Q39145691 |
| | Quantification in molecular ultrasound imaging: a comparative study in mice between healthy liver and a human hepatocellular carcinoma xenograft | Q39235504 |
| | Parametric imaging using subharmonic signals from ultrasound contrast agents in patients with breast lesions. | Q39964752 |
| | Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody | Q39991117 |
| | Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects | Q40024036 |
| | Tumour angiogenesis | Q40109033 |
| | Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature | Q40187867 |
| | Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography | Q40276910 |
| | Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool | Q40398499 |
| | Quantitative angiogenesis assays: progress and problems | Q41634715 |
| | Arterial-phase contrast-enhanced ultrasonography for evaluating anti-angiogenesis treatment: a pilot study | Q42688136 |
| | Correlation of quantified contrast-enhanced sonography with in vivo tumor response | Q43106738 |
| | Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography | Q43166821 |
| | Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55. | Q43672998 |
| | Quantitative morphometric analysis of the microcirculation in prostate carcinoma | Q43718835 |
| | Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38). | Q44035899 |
| | Standardization of dynamic contrast-enhanced ultrasound for the evaluation of antiangiogenic therapies: the French multicenter Support for Innovative and Expensive Techniques Study. | Q44560343 |
| | Angiogenesis model for ultrasound contrast research: exploratory study | Q45142678 |
| | Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma | Q45952675 |
| | Angiogenesis: noninvasive quantitative assessment with contrast-enhanced functional US in murine model | Q46486160 |
| | Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. | Q46689400 |
| | The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2-targeted microbubbles (BR55). | Q47283269 |
| | Successful left ventricular opacification following peripheral venous injection of sonicated contrast agent: an experimental evaluation | Q48523392 |
| | Ultrasound is now better than mammography for the detection of invasive breast cancer. | Q50487903 |
| | Maximum-likelihood estimation for indicator dilution analysis. | Q51140916 |
| P433 | issue | 1 | |
| P921 | main subject | contrast-enhanced ultrasound | Q500458 |
| | tumor angiogenesis | Q110495869 |
| P304 | page(s) | 41-52 | |
| P577 | publication date | 2014-02-01 | |
| P1433 | published in | Imaging in medicine | Q27723296 |
| P1476 | title | Recent developments in dynamic contrast-enhanced ultrasound imaging of tumor angiogenesis | |
| P478 | volume | 6 | |